Skip to search formSkip to main contentSkip to account menu

VGX-3100

Known as: HPV DNA Plasmids Therapeutic Vaccine VGX-3100 
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Papillomavirus VaccinesVaccines, DNA

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Clinical and Immunologic Biomarkers for Regression of High Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 Infection after Immunotherapy with VGX-3100 in a Phase IIb Clinical Trial
We have previously demonstrated proof-of-principle of VGX-3100, an immunotherapy which targets HPV16/18 E6 and E7, in a Phase… 
2015
2015
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and…
Meeting abstracts Oropharyngeal HNSCCa is frequently associated with HPV infection. DNA-based Immunotherapy with plasmids… 
2015
2015
Gynaecological cancer: Therapeutic HPV vaccine holds promise
2015
2015
Abstract CT131: HPV specific immunotherapy for cervical intraepithelial neoplasia using VGX-3100 induces regression of cervical lesions and potent T-cell responses: Results from a randomized, double…
The advent of an immunotherapy that imparts a significant impact on the clinical status of advanced cervical intraepithelial… 
2015
2015
HPV specific immunotherapy for cervical intraepithelial neoplasia using VGX-3100 induces regression of cervical lesions and potent T cell responses: results from a randomized, double-blind, placebo…
Here we report the results of a Phase II study assessing the safety and efficacy of VGX-3100 in 167 women with biopsy-proven… 
2015
2015
ITOC2 – 020. VGX-3100 Immunotherapy for CIN2/3 Induces regression of cervical lesions and viral clearance (Phase II study): Implications for treatment of HPV associated cancers
2014
2014
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind…
The Phase II study, designated HPV-003 (NCT01304524), assessed the safety and efficacy of VGX-3100 in 167 women with biopsy… 
2014
2014
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial.
3101 Background: Despite the development of highly effective prophylactic vaccines against human papillomavirus (HPV) types 16… 
2012
2012
New vaccine for cervical cancer shows promise
2012
2012
Cervical cancer immunotherapy: Induction of HPV specific CTLs in human volunteers after VGX-3100 immunization
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)